CN104902914B - 高纯度和优异产量的正确折叠的依那西普 - Google Patents

高纯度和优异产量的正确折叠的依那西普 Download PDF

Info

Publication number
CN104902914B
CN104902914B CN201380058650.5A CN201380058650A CN104902914B CN 104902914 B CN104902914 B CN 104902914B CN 201380058650 A CN201380058650 A CN 201380058650A CN 104902914 B CN104902914 B CN 104902914B
Authority
CN
China
Prior art keywords
etanercept
protein
resin
mixed mode
separation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201380058650.5A
Other languages
English (en)
Chinese (zh)
Other versions
CN104902914A (zh
Inventor
荒川力
道格拉斯·法勒
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Coherus Oncology Inc
Original Assignee
Coherus Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50233493&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN104902914(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Coherus Biosciences Inc filed Critical Coherus Biosciences Inc
Priority to CN201811633164.2A priority Critical patent/CN110051823A/zh
Publication of CN104902914A publication Critical patent/CN104902914A/zh
Application granted granted Critical
Publication of CN104902914B publication Critical patent/CN104902914B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/165—Extraction; Separation; Purification by chromatography mixed-mode chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Analytical Chemistry (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
CN201380058650.5A 2012-09-11 2013-09-10 高纯度和优异产量的正确折叠的依那西普 Expired - Fee Related CN104902914B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201811633164.2A CN110051823A (zh) 2012-09-11 2013-09-10 高纯度和优异产量的正确折叠的依那西普

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261699552P 2012-09-11 2012-09-11
US61/699,552 2012-09-11
PCT/US2013/058994 WO2014043103A1 (en) 2012-09-11 2013-09-10 Correctly folded etanercept in high purity and excellent yield

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN201811633164.2A Division CN110051823A (zh) 2012-09-11 2013-09-10 高纯度和优异产量的正确折叠的依那西普

Publications (2)

Publication Number Publication Date
CN104902914A CN104902914A (zh) 2015-09-09
CN104902914B true CN104902914B (zh) 2019-01-01

Family

ID=50233493

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201380058650.5A Expired - Fee Related CN104902914B (zh) 2012-09-11 2013-09-10 高纯度和优异产量的正确折叠的依那西普
CN201811633164.2A Pending CN110051823A (zh) 2012-09-11 2013-09-10 高纯度和优异产量的正确折叠的依那西普

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201811633164.2A Pending CN110051823A (zh) 2012-09-11 2013-09-10 高纯度和优异产量的正确折叠的依那西普

Country Status (33)

Country Link
US (6) US20140072560A1 (https=)
EP (1) EP2895188B1 (https=)
JP (3) JP2015533797A (https=)
KR (2) KR102250937B1 (https=)
CN (2) CN104902914B (https=)
AR (1) AR092532A1 (https=)
AU (2) AU2013315750B9 (https=)
BR (1) BR112015005161A2 (https=)
CA (1) CA2882551A1 (https=)
CL (1) CL2015000572A1 (https=)
CO (1) CO7400876A2 (https=)
CY (1) CY1120062T1 (https=)
DK (1) DK2895188T3 (https=)
DO (1) DOP2015000055A (https=)
EA (1) EA031324B1 (https=)
EC (1) ECSP15014138A (https=)
ES (1) ES2657377T3 (https=)
HR (1) HRP20180182T1 (https=)
HU (1) HUE036524T2 (https=)
IL (2) IL237311B (https=)
IN (1) IN2015KN00452A (https=)
LT (1) LT2895188T (https=)
MX (2) MX360044B (https=)
NO (1) NO2972131T3 (https=)
PE (2) PE20200607A1 (https=)
PL (1) PL2895188T3 (https=)
PT (1) PT2895188T (https=)
RS (1) RS57013B1 (https=)
SG (1) SG11201501460RA (https=)
SI (1) SI2895188T1 (https=)
SM (1) SMT201800163T1 (https=)
TW (2) TWI609877B (https=)
WO (1) WO2014043103A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112876567A (zh) * 2019-11-29 2021-06-01 广东菲鹏制药股份有限公司 Fc融合蛋白及其纯化方法

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2007015476A (es) 2005-06-14 2008-02-25 Amgen Inc Formulaciones de proteina autoamortiguadoras.
HK1200718A1 (en) 2011-10-18 2015-08-14 科荣生生物科学公司 Etanercept formulations stabilized with sodium chloride
US10485869B2 (en) 2011-10-18 2019-11-26 Coherus Biosciences, Inc. Etanercept formulations stabilized with meglumine
EA031324B1 (ru) * 2012-09-11 2018-12-28 Кохерус Байосайенсис, Инк. Правильно свернутый этанерцепт с высокой чистотой и высоким уровнем выхода
AU2015273049B2 (en) * 2014-06-13 2019-11-14 Lupin Limited Process for the purification of TNFR:Fc fusion protein
ES2733298T3 (es) 2014-07-18 2019-11-28 Sandoz Ag Cuantificación de TNFR2:Fc plegado erróneamente
EP3241849A4 (en) * 2014-12-31 2018-06-20 LG Chem, Ltd. Method for producing tnfr-fc fusion protein containing target content of impurities
KR20170138426A (ko) 2015-03-13 2017-12-15 삼성바이오에피스 주식회사 항-tnf-알파 폴리펩티드 조성물 및 그 용도
SG11201804083QA (en) * 2015-11-18 2018-06-28 Merck Patent Gmbh Opposite ph-salt gradients for improved protein separations
US20180327447A1 (en) * 2015-11-18 2018-11-15 Merck Patent Gmbh Improved protein separation in ion exchange chromatography
CN109563124A (zh) * 2016-06-17 2019-04-02 豪夫迈·罗氏有限公司 多特异性抗体的纯化
AU2017345490B2 (en) * 2016-10-21 2022-07-07 Amgen Inc. Pharmaceutical formulations and methods of making the same
WO2018119142A1 (en) 2016-12-21 2018-06-28 Amgen Inc. Anti-tnf alpha antibody formulations
CA3057286A1 (en) * 2017-03-24 2018-09-27 Council Of Scientific And Industrial Research A process for the purification of recombinant antibody fragments
US11253569B2 (en) 2018-05-03 2022-02-22 Seattle Children's Hospital Methods of treating Kawasaki Disease
EP4142792A4 (en) 2020-05-01 2024-11-27 Kashiv Biosciences, LLC An improved process of purification of protein
US20240156907A1 (en) * 2021-03-16 2024-05-16 Kashiv Biosciences, Llc Novel formulation of fusion protein
WO2022234412A1 (en) * 2021-05-03 2022-11-10 Lupin Limited A process for purification of fc-fusion proteins
CN118414350A (zh) * 2021-10-19 2024-07-30 阿特根公司 纯化具有igg fc结构域的融合蛋白的方法
EP4696709A1 (en) * 2024-12-06 2026-02-18 Qilu Pharmaceutical Co., Ltd. Variants of etanercept and related processes

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102239177A (zh) * 2008-02-29 2011-11-09 比奥根艾迪克Ma公司 纯化的免疫球蛋白融合蛋白及其纯化方法

Family Cites Families (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5605690A (en) 1989-09-05 1997-02-25 Immunex Corporation Methods of lowering active TNF-α levels in mammals using tumor necrosis factor receptor
US5395760A (en) 1989-09-05 1995-03-07 Immunex Corporation DNA encoding tumor necrosis factor-α and -β receptors
ATE194384T1 (de) 1989-09-12 2000-07-15 Hoffmann La Roche Tnf-bindende proteine
IT1240314B (it) 1989-09-28 1993-12-07 Immunobiology Research Institutes, Inc. Formulazioni acquose stabilizzate di piccoli peptidi.
ES2120949T4 (es) 1990-06-28 2011-12-29 Sanofi-Aventis Deutschland Gmbh 50% Proteinas de fusión con porciones de inmunoglobulinas, su preparación y empleo.
KR100232688B1 (ko) 1992-09-15 1999-12-01 스코트 쥐. 홀퀴스트 종양 괴사 인자 길항제를 함유하는 tnf-의존성 염증 치료용 제약 조성물
EP0852951A1 (de) 1996-11-19 1998-07-15 Roche Diagnostics GmbH Stabile lyophilisierte pharmazeutische Zubereitungen von mono- oder polyklonalen Antikörpern
US7294481B1 (en) 1999-01-05 2007-11-13 Immunex Corporation Method for producing recombinant proteins
AU4363200A (en) 1999-04-19 2000-11-02 Immunex Corporation Soluble tumor necrosis factor receptor treatment of medical desorders
US20010021380A1 (en) 1999-04-19 2001-09-13 Pluenneke John D. Soluble tumor necrosis factor receptor treatment of medical disorders
US20040220103A1 (en) 1999-04-19 2004-11-04 Immunex Corporation Soluble tumor necrosis factor receptor treatment of medical disorders
WO2001058473A1 (en) 2000-02-10 2001-08-16 Wyeth Method of treating or inhibiting cellular injury or cell death
US8632778B2 (en) 2000-08-11 2014-01-21 Chugai Seiyaku Kabushiki Kaisha Stabilized anti-interleukin-6 antibody-containing preparations
JP2005505494A (ja) 2001-02-23 2005-02-24 イミュネックス・コーポレーション 活性タンパク質の回収増加
PT1946776T (pt) 2002-02-27 2017-03-17 Immunex Corp Composição de tnfr-fc estabilizada compreendendo arginina
WO2004017955A1 (en) * 2002-08-22 2004-03-04 Vasopharm Biotech Gmbh L-arginine containing pharmaceutical composition
US20040115263A1 (en) 2002-08-26 2004-06-17 Robertson David W. Use of bupropion for treating restless legs syndrome
JP4980048B2 (ja) 2003-02-28 2012-07-18 アレス トレーディング ソシエテ アノニム 腫瘍壊死因子結合タンパク質の液体製剤
US20060177444A1 (en) 2003-03-20 2006-08-10 Tatsuo Horizoe Concomitant drug as therapeutic agent for inflammatory bowel disease
SG145712A1 (en) 2003-08-01 2008-09-29 Amgen Inc Crystalline tumor necrosis factor receptor 2 polypeptides
HRP20130098T1 (hr) 2003-10-14 2013-02-28 F. Hoffmann - La Roche Ag MAKROCIKLIÄŚKE KARBOKSILNE KISELINE I ACILSULFONAMIDNI SPOJEVI KAO INHIBITORI REPLIKACIJE HCV-a
AU2005216847B2 (en) * 2004-02-27 2010-04-01 Cytiva Bioprocess R&D Ab A process for the purification of antibodies
JP5554466B2 (ja) 2004-03-01 2014-07-23 味の素株式会社 抗ヒトＴＮＦ−α抗体活性低下抑制剤
CA2557046A1 (en) 2004-03-05 2005-10-13 John Crowley Process for cell culturing by continuous perfusion and alternating tangential flow
US20070196364A1 (en) 2004-07-27 2007-08-23 Human Genome Sciences, Inc. Pharmaceutical Formulation and Process
TWI364458B (en) 2004-08-27 2012-05-21 Wyeth Res Ireland Ltd Production of tnfr-lg
JP5339901B2 (ja) 2005-05-10 2013-11-13 バイオジェン・アイデック・エムエイ・インコーポレイテッド 炎症傷害の処置および評価
KR101367544B1 (ko) 2005-06-10 2014-02-26 추가이 세이야쿠 가부시키가이샤 메글루민을 함유하는 단백질 제제의 안정화제, 및 그의이용
CN101584858A (zh) 2005-12-20 2009-11-25 布里斯托尔-迈尔斯斯奎布公司 稳定蛋白质制剂
BRPI0620316A2 (pt) 2005-12-21 2011-11-08 Wyeth Corp formulações de proteìnas com viscosidades reduzida e seus usos
CA2638811A1 (en) 2006-02-03 2007-08-16 Medimmune, Llc Protein formulations
KR101516823B1 (ko) 2006-03-17 2015-05-07 바이오겐 아이덱 엠에이 인코포레이티드 안정화된 폴리펩티드 조성물
JP2009534390A (ja) 2006-04-21 2009-09-24 アムジェン インコーポレイテッド 生物医薬品製剤のための緩衝剤
EP2081553B1 (en) 2006-10-06 2020-08-12 Amgen Inc. Stable antibody formulations
US7705132B2 (en) 2006-10-20 2010-04-27 Amgen Inc. Stable polypeptide formulations
EP2064315B1 (en) 2006-11-03 2015-05-13 Wyeth LLC Glycolysis-inhibiting substances in cell culture
JP5577098B2 (ja) 2006-12-21 2014-08-20 アムジエン・インコーポレーテツド ポリペプチドを含有する安定な緩衝化された製剤
US7691980B2 (en) * 2007-01-09 2010-04-06 Bio-Rad Laboratories, Inc. Enhanced capacity and purification of antibodies by mixed mode chromatography in the presence of aqueous-soluble nonionic organic polymers
CA2679941C (en) 2007-03-02 2016-09-20 Wyeth Use of copper and glutamate in cell culture for production of polypeptides
EP2014760A1 (en) 2007-06-13 2009-01-14 CMC Biopharmaceuticals A/S A method for producing a biopolymer (e.g. polypeptide) in a continuous fermentation process
EP2170390B1 (en) 2007-06-14 2018-11-07 Biogen MA Inc. Natalizumab antibody formulations
TWI543768B (zh) 2007-11-30 2016-08-01 艾伯維生物技術有限責任公司 蛋白質調配物及製造其之方法
JP5677943B2 (ja) * 2008-06-05 2015-02-25 アフィボディ・アーベーＡｆｆｉｂｏｄｙ Ａｂ ポリペプチド
WO2011015926A1 (en) * 2009-08-03 2011-02-10 Avesthagen Limited A process of fermentation, purification and production of recombinant soluble tumour necrosis factor alfa receptor (tnfr) - human igg fc fusion protein
US8536316B2 (en) 2009-08-07 2013-09-17 Emd Millipore Corporation Methods for purifying a target protein from one or more impurities in a sample
CN104059955A (zh) 2009-08-11 2014-09-24 弗·哈夫曼-拉罗切有限公司 在无谷氨酰胺的细胞培养基中的蛋白质生产
US20120208986A1 (en) * 2009-10-20 2012-08-16 Wenger Marc D Use of mixed mode chromatography for the capture and purification of basic antibody products
US20130052195A1 (en) 2009-12-23 2013-02-28 Emergent Product Development Seattle,LLC Compositions Comprising TNF-alpha and IL-6 Antagonists and Methods of Use Thereof
US9428727B2 (en) 2010-04-26 2016-08-30 Novartis Ag Cell culture medium
EP2568960B1 (en) * 2010-05-10 2018-06-06 Intas Pharmaceuticals Ltd. Liquid formulation of polypeptides containing an fc domain of an immunoglobulin
EP2598167B1 (en) 2010-07-30 2015-04-01 Arecor Limited Stabilized aqueous antibody compositions
EP2606119A1 (en) 2010-08-20 2013-06-26 Wyeth LLC Cell culture of growth factor-free adapted cells
EP2611904A2 (en) 2010-08-31 2013-07-10 Friesland Brands B.V. Culture medium for eukaryotic cells
WO2012051147A1 (en) * 2010-10-11 2012-04-19 Abbott Laboratories Processes for purification of proteins
BR112013026883A2 (pt) 2011-04-20 2021-12-07 Sandoz Ag Composição farmacêutica, kit compreendendo uma composição e método de produção de uma composição farmacêutica
UY34105A (es) 2011-06-03 2012-07-31 Lg Life Sciences Ltd Formulación líquida estable de etanercept
CN113244374A (zh) 2011-07-01 2021-08-13 生物基因Ma公司 无精氨酸的tnfr:fc-融合多肽组合物及使用方法
DK2726600T3 (en) 2011-07-01 2017-05-15 Amgen Inc Mammalian Cell Culture
BR112014000352A2 (pt) * 2011-07-08 2017-02-14 Merck Sharp & Dohe Corp método de purificar uma proteína de fusão-fc, proteínas de fusão contendo fc purificada, tnfr:fc purificada, e tnfr:fc elevadamente purificada
KR101454316B1 (ko) * 2011-08-17 2014-10-27 한화케미칼 주식회사 활성형 ＴＮＦＲ-Ｆｃ 융합 단백질을 제조하는 방법
US10485869B2 (en) * 2011-10-18 2019-11-26 Coherus Biosciences, Inc. Etanercept formulations stabilized with meglumine
HK1200718A1 (en) * 2011-10-18 2015-08-14 科荣生生物科学公司 Etanercept formulations stabilized with sodium chloride
IN2015KN00005A (https=) * 2012-07-09 2015-07-31 Coherus Biosciences Inc
EA031324B1 (ru) * 2012-09-11 2018-12-28 Кохерус Байосайенсис, Инк. Правильно свернутый этанерцепт с высокой чистотой и высоким уровнем выхода
EP3175282B1 (en) * 2014-07-31 2021-06-09 Mtt Innovation Incorporated Numerical approaches for free-form lensing: area parameterization free-form lensing
US20160108634A1 (en) * 2014-10-16 2016-04-21 Ronald Uphold Pool Cover Hanger Device

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102239177A (zh) * 2008-02-29 2011-11-09 比奥根艾迪克Ma公司 纯化的免疫球蛋白融合蛋白及其纯化方法

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112876567A (zh) * 2019-11-29 2021-06-01 广东菲鹏制药股份有限公司 Fc融合蛋白及其纯化方法

Also Published As

Publication number Publication date
DOP2015000055A (es) 2015-04-30
SMT201800163T1 (it) 2018-05-02
WO2014043103A1 (en) 2014-03-20
MX2018012749A (es) 2020-11-12
CN110051823A (zh) 2019-07-26
CL2015000572A1 (es) 2016-02-05
HRP20180182T1 (hr) 2018-04-20
US20140072560A1 (en) 2014-03-13
EP2895188B1 (en) 2017-11-15
ES2657377T3 (es) 2018-03-05
KR102133699B1 (ko) 2020-07-14
EA031324B1 (ru) 2018-12-28
LT2895188T (lt) 2018-04-10
PT2895188T (pt) 2018-02-08
SG11201501460RA (en) 2015-04-29
CN104902914A (zh) 2015-09-09
IL267452A (en) 2019-08-29
EP2895188A4 (en) 2016-05-25
AU2018247244A1 (en) 2018-11-01
JP2021100929A (ja) 2021-07-08
TW201425331A (zh) 2014-07-01
PE20200607A1 (es) 2020-03-10
JP2015533797A (ja) 2015-11-26
IN2015KN00452A (https=) 2015-07-17
HUE036524T2 (hu) 2018-07-30
AU2013315750B9 (en) 2018-11-15
SI2895188T1 (en) 2018-05-31
EP2895188A1 (en) 2015-07-22
US10947306B2 (en) 2021-03-16
US20190300600A1 (en) 2019-10-03
US20190330325A1 (en) 2019-10-31
AU2013315750B2 (en) 2018-07-12
ECSP15014138A (es) 2016-01-29
TW201803593A (zh) 2018-02-01
KR20200085937A (ko) 2020-07-15
CO7400876A2 (es) 2015-09-30
TWI609877B (zh) 2018-01-01
US20190300601A1 (en) 2019-10-03
PL2895188T3 (pl) 2018-06-29
US10954293B2 (en) 2021-03-23
US20190300602A1 (en) 2019-10-03
TWI716649B (zh) 2021-01-21
AU2018247244B2 (en) 2020-05-28
JP2019038817A (ja) 2019-03-14
AU2013315750A1 (en) 2015-03-05
KR20150056601A (ko) 2015-05-26
KR102250937B1 (ko) 2021-05-12
NO2972131T3 (https=) 2018-04-21
AR092532A1 (es) 2015-04-22
IL237311B (en) 2019-07-31
DK2895188T3 (en) 2018-02-26
US10954295B2 (en) 2021-03-23
PE20150996A1 (es) 2015-08-01
RS57013B1 (sr) 2018-05-31
EA201590542A1 (ru) 2015-07-30
CA2882551A1 (en) 2014-03-20
US11001627B2 (en) 2021-05-11
BR112015005161A2 (pt) 2017-07-04
US10954294B2 (en) 2021-03-23
IL267452B (en) 2021-05-31
CY1120062T1 (el) 2018-12-12
US20180037642A1 (en) 2018-02-08
MX360044B (es) 2018-10-19
MX2015003090A (es) 2015-07-14
JP6913066B2 (ja) 2021-08-04
IL237311A0 (en) 2015-04-30

Similar Documents

Publication Publication Date Title
CN104902914B (zh) 高纯度和优异产量的正确折叠的依那西普
RU2736339C1 (ru) Слитый белок человеческого фактора свертывания IХ (FIX), способ его получения и применения
CN103998061A (zh) 使用木糖醇稳定的依那西普制剂
TWI691512B (zh) Ｆｃ融合高親和性ＩｇＥ受體α鏈
TW201443234A (zh) 重組酵母菌轉形株及使用該轉形株製備免疫球蛋白ｆｃ片段之方法
HK40009767A (zh) 高纯度和优异产量的正确折叠的依那西普

Legal Events

Date Code Title Description
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20190101

CF01 Termination of patent right due to non-payment of annual fee